MTMorgane Thomsen

Morgane Thomsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Morgane Thomsen has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Combined muscarinic receptor M 1 and M 4 stimulation reverses cocaine-induced attention deficits in male mice

    by Lærke Bornø, Marie Søndergaard Forsbøl, Oguzcan Yüksel, Veronika Bonnevie, Abhishek Shankar Balakrishnan, Jesper T. Andreasen, Craig W. Lindsley, Morgan Thomsen

    Background: Cocaine use and cocaine use disorder (CUD) are increasing public health concerns that lack effective treatments. CUD is a chronic illness characterized by relapse, altered activity in the prefrontal cortex and neurocognitive symptoms. Pharmacologically stimulating muscarinic acetylcholine receptors M 1 and/or M 4 has been shown to counteract abuse-related effects of cocaine and, independently, to have pro-cognitive effects. Objectives: We tested the hypotheses that (1) withdrawal from a subchronic cocaine regimen in mice will negatively impact attention and impulsivity and (2) pharmacological stimulation of M 1 , M 4 , or M 1 + M 4 receptors will blunt or reverse these cocaine-induced impairments. Methods: Using a touchscreen rodent continuous performance test, male C57BL/6JRj mice were trained to respond to a target and withhold responses to a non-target stimulus. Mice received 20 mg/kg cocaine for 5 days and 30 mg/kg for 14 days. Then, the effect of treatment with the muscarinic M 1 agonist VU0364572 (3.2 mg/kg) and the M 4 PAM VU0152100 (1.8 mg/kg) was assessed in test probes challenging attention (variable stimulus duration) and impulsivity (variable intertrial interval), respectively. Results: Cocaine exposure significantly and consistently impaired measures of attention (discriminability, accuracy), with less consistent effects on impulsivity (false alarm rate, premature responses). Treatment with combined VU0364572 + VU0152100 reversed cocaine-induced attention deficits, while each drug alone had little effect. Conclusions: These findings support the hypothesis that targeting M 1 and M 4 receptors can rescue cocaine-induced cognitive symptoms. Because cognitive impairments are thought to contribute to relapse to cocaine use, these results further support M 1 /M 4 receptors as promising targets to treat CUD.

  • Open Access

    Sprague Dawley rats from different vendors vary in the modulation of prepulse inhibition of startle (PPI) by dopamine, acetylcholine, and glutamate drugs

    by S.B. Caine, S. Plant, K. Furbish, M. Yerton, E. Smaragdi, B. Niclou, J.M. Lorusso, J.Y. Chang, C. Bitter, A. Basu, et al.

    Rationale: Rodent vendors are often utilized interchangeably, assuming that the phenotype of a given strain remains standardized between colonies. Several studies, however, have found significant behavioral and physiological differences between Sprague Dawley (SD) rats from separate vendors. Prepulse inhibition of startle (PPI), a form of sensorimotor gating in which a low-intensity leading stimulus reduces the startle response to a subsequent stimulus, may also vary by vendor. Differences in PPI between rat strains are well known, but divergence between colonies within the SD strain lacks thorough examination. Objectives: We explored intrastrain variation in PPI by testing SD rats from two vendors: Envigo and Charles River (CR). Methods: We selected drugs acting on four major neurotransmitter systems that have been repeatedly shown to modulate PPI: dopamine (apomorphine; 0.5, 1.5, 3.0 mg/kg), acetylcholine (scopolamine; 0.1, 0.5, 1.0 mg/kg), glutamate (dizocilpine; 0.5, 1.5, 2.5 mg/kg), and serotonin (2,5-Dimethoxy-4-iodoamphetamine, DOI; 0.25, 0.5, 1.0 mg/kg). We determined PPI and startle amplitude for each drug in male and female Envigo and CR SD rats. Results: SD rats from Envigo showed dose-dependent decreases in PPI after apomorphine, scopolamine, or dizocilpine administration, without significant effects on startle amplitude. SD rats from CR were less sensitive to modulation of PPI and/or more sensitive to modulation of startle amplitude, across the three drugs. Conclusions: SD rats showed vendor differences in sensitivity to pharmacological modulation of PPI and startle. We encourage researchers to sample rats from separate vendors before experimentation to identify the most suited source of subjects for their specific endpoints.


  • Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice.

    by Marie-Louise Allingbjerg, Stine N. Hansen, Anna Secher, Morgane Thomsen

    Glucagon-like peptide 1 (GLP-1) receptor agonists can decrease alcohol intake by central mechanisms that are still poorly understood. The lateral septum (LS) and the ventral/caudal part of the hippocampus are enriched in GLP-1 receptors, and activity in these regions was shown to modulate reward-related behaviors. Using microinfusions of the GLP-1 receptor agonist exendin-4 in mice trained to self-administer oral alcohol in an operant assay, we tested whether pharmacological stimulation of GLP-1 receptors in hippocampus and LS decrease alcohol self-administration. We report that infusion of exendin-4 in the ventral hippocampus or LS was sufficient to reduce alcohol self-administration with as large effect sizes as we previously reported with systemic exendin-4 administration. Infusion of exendin-4 into the nucleus accumbens also reduced alcohol self-administration, as anticipated based on earlier reports, while infusion of exendin-4 into the caudate-putamen (dorsal striatum) had little effect, consistent with lack of GLP-1 receptor expression in this region. The distribution of exendin-4 after infusion into the LS or caudate putamen was visualized using a fluorescently labeled ligand. These findings add to our understanding of the circuit-level mechanisms underlying the ability of GLP-1 receptor agonists to reduce alcohol self-administration. (PsycInfo Database Record (c) 2023 APA, all rights reserved).


  • Open Access

    Sprague Dawley Rats from Different Vendors Vary in the Modulation of Prepulse Inhibition of Startle (PPI) by Dopamine, Acetylcholine, and Glutamate Drugs

    by S. Barak Caine, Morgane Thomsen

    ID 53081 Poster Board 415 Rationale: Rodent vendors are often utilized interchangeably assuming that the phenotype of a given strain remains standardized between colonies. Several studies, however, have found significant behavioral and physiological differences between Sprague Dawley (SD) rats from separate vendors. Prepulse inhibition of startle (PPI), a form of sensorimotor gating in which a low-intensity leading stimulus reduces the startle response to a subsequent stimulus, may also vary by vendor. Differences in PPI between rat strains are well known, but divergence between colonies within the SD strain lacks thorough examination. Objectives: We explored intrastrain variation in PPI by testing SD rats from two vendors: Envigo and Charles River. Methods: We selected drugs acting on four major neurotransmitter systems that have been repeatedly shown to modulate PPI: dopamine (apomorphine; 0.5, 1.5, 3.0 mg/kg), acetylcholine (scopolamine; 0.1, 0.5, 1.0 mg/kg), glutamate (dizocilpine; 0.5, 1.5, 2.5 mg/kg), and serotonin (2,5-Dimethoxy-4-iodoamphetamine, DOI; 0.25, 0.5, 1.0 mg/kg). We determined PPI and startle amplitude for each drug in male and female Envigo and Charles River SD rats. Results: SD rats from Envigo showed dose-dependent decreases in PPI after apomorphine, scopolamine, or dizocilpine administration, without significant effects on startle amplitude. SD rats from CR were less sensitive to modulation of PPI and/or more sensitive to modulation of startle amplitude, across the three drugs. Conclusions: SD rats showed vendor differences in sensitivity to pharmacological modulation of PPI and startle. We encourage researchers to sample rats from separate vendors before experimentation to identify the most suited source of subjects for their specific endpoints. McLean Hospital funding to SB Caine; NIH grant R01AA025071 to M Thomsen

  • Open Access

    Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice

    by Claudia Díaz-Megido, Morgane Thomsen

    Rationale: Alcohol use disorder remains a leading cause of preventable deaths, and current treatments have limited efficacy. Glucagon-like peptide 1 (GLP-1) receptor agonists can reduce alcohol drinking in preclinical studies, but mechanisms are still not fully understood, and data in female subjects are scarce.Objectives: To assess whether the GLP-1 receptor agonist exendin-4 could decrease alcohol-seeking behavior in the absence of alcohol consumption or intoxication, to compare the potency and efficacy of exendin-4 in the reduction of alcohol seeking vs. alcohol taking, and to compare effects between male and female mice.Methods: Male and female C57BL/6J mice were trained to self-administer 20% alcohol under an FR 1 schedule of reinforcement. After extinction, systemic exendin-4 (saline, 1.8, and 3.2 μg/kg) was tested in cue-induced reinstatement of alcohol seeking. Effects of exendin-4 on alcohol self-administration were tested in a separate group.Results: Exendin-4 suppressed reinstatement of alcohol seeking to extinction levels, at both doses, in the male mice, but had no effect in the female mice. Both doses of exendin-4 also significantly decreased alcohol self-administration in male mice; females again showed less pronounced effects.Conclusions: In male mice, exendin-4 appeared more effective at suppressing alcohol seeking in the absence of alcohol relative to alcohol self-administration, consistent with modulation of alcohol reward or inhibitory control, rather than satiety or aversive effects of alcohol. We saw marked sex differences with less effect of exendin-4 in female mice, and it will be important to include both sexes in further investigations into GLP-1 receptor agonists.


  • Open Access

    Behavioral and biochemical effects of alcohol withdrawal in female C3H/HeNRj and C57BL/6JRj mice

    by Simone Tonetto, Pia Weikop, Tomasz Brudek, Morgane Thomsen

    Background: Alcohol use disorder (AUD) is a major problem of our society and is often characterized and worsened by relapse. Prolonged alcohol exposure leads to numerous biochemical alterations that, upon cessation of alcohol intake, cause an array of immediate and lasting withdrawal symptoms. Acute withdrawal and neuroinflammation can be harmful in themselves, and lasting withdrawal symptoms contribute to relapse. Here, we conducted an initial feasibility study assessing several behavioral and neurochemical factors in female C3H/HeNRj (C3H) and C57BL/6JRj (B6) mice to determine which strain showed the clearest alcohol withdrawal symptoms during long-term abstinence and neurochemical alterations following re-exposure.Methods: Female C3H and B6 mice (n = 12 per group/strain) were intermittently exposed to alcohol-containing or control liquid diets for 3 weeks. Acute and prolonged withdrawal symptoms were assessed over a period of 3 weeks using a battery of behavioral test, comprised of alcohol self-administration, anhedonia, hyperalgesia, anxiety-like and depressive-like disturbances. Brain inflammation was measured by multiplex cytokine assay. Monoamine levels in the hippocampus and striatum, as well as exploratory analyses of cations levels in the cerebellum, were assessed by High-Performance Liquid Chromatography (HPLC).Results: Both C3H and B6 alcohol-exposed mice displayed decreased saccharin intake or preference and higher stress levels assessed by ultrasonic vocalizations (USVs) recordings. B6 but not C3H alcohol-exposed mice also exhibited a slower decline of alcohol oral self-administration (OSA), hyperalgesia, elevated brain TNF-α and elevated serotonin turnover.Conclusion: Our findings highlight the suitability of the B6 strain to study the behavioral and neurochemical alterations caused by alcohol withdrawal and the potential efficacy of experimental treatments, not only in early detoxification, but also in prolonged abstinence. The feasibility of these assays is important because long-lasting withdrawal symptoms are often the main cause of relapse in alcohol-dependent patients.


  • Open Access

    Effects of acute and repeated administration of the selective M4 PAM VU0152099 on cocaine versus food choice in male rats

    by Morgane Thomsen, Jill R. Crittenden, Craig W. Lindsley, Ann M. Graybiel

    Ligands that stimulate muscarinic acetylcholine receptors 1 and 4 (M1, M4) have shown promising effects as putative pharmacotherapy for cocaine use disorder in rodent assays. We have previously shown reductions in cocaine effects with acute M4 stimulation, as well as long‐lasting, delayed reductions in cocaine taking and cocaine seeking with combined M1/M4 receptor stimulation or with M1 stimulation alone. M4 stimulation opposes dopaminergic signalling acutely, but direct dopamine receptor antagonists have proved unhelpful in managing cocaine use disorder because they lose efficacy with long‐term administration. It is therefore critical to determine whether M4 approaches themselves can remain effective with repeated or chronic dosing. We assessed the effects of repeated administration of the M4 positive allosteric modulator (PAM) VU0152099 in rats trained to choose between intravenous cocaine and a liquid food reinforcer to obtain quantitative measurement of whether M4 stimulation could produce delayed and lasting reduction in cocaine taking. VU0152099 produced progressively augmenting suppression of cocaine choice and cocaine intake, but produced neither rebound nor lasting effects after treatment ended. To compare and contrast effects of M1 versus M4 stimulation, we tested whether the M4 PAM VU0152100 suppressed cocaine self‐administration in mice lacking CalDAG‐GEFI signalling factor, required for M1‐mediated suppression of cocaine self‐administration. CalDAG‐GEFI ablation had no effect on M4‐mediated suppression of cocaine self‐administration. These findings support the potential usefulness of M4 PAMs as pharmacotherapy to manage cocaine use disorder, alone or in combination with M1‐selective ligands, and show that M1 and M4 stimulation modulate cocaine‐taking behaviour by distinct mechanisms.


  • Top Cited Papers

    The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders

    by Mette Kruse Klausen, Morgane Thomsen, Gitta Wortwein, Anders Fink‐Jensen

    Drug, alcohol and tobacco use disorders are a global burden affecting millions of people. Despite decades of research, treatment options are sparse or missing, and relapse rates are high. Glucagon‐like peptide 1 (GLP‐1) is released in the small intestine, promotes blood glucose homeostasis, slows gastric emptying and reduces appetite. GLP‐1 receptor agonists approved for treating Type 2 diabetes mellitus and obesity have received attention as a potential anti‐addiction treatment. Studies in rodents and non‐human primates have demonstrated a reduction in intake of alcohol and drugs of abuse, and clinical trials have been initiated to investigate whether the preclinical findings can be translated to patients. This review will give an overview of current findings and discuss the possible mechanisms of action. We suggest that effects of GLP‐1 in alcohol and substance use disorders is mediated centrally, at least partly through dopamine signalling, but precise mechanisms are still to be uncovered.LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc


  • Open Access

    Effects of acute and repeated administration of the selective M 4 PAM VU0152099 on cocaine vs. food choice in male rats

    by Morgane Thomsen, Jill R. Crittenden, Craig W. Lindsley, Ann M. Graybiel

    A bstract: Ligands that stimulate muscarinic acetylcholine receptors 1 and 4 (M 1 , M 4 ) have shown promising effects as putative pharmacotherapy for cocaine use disorder in rodent assays. We have previously shown reductions in cocaine effects with acute M 4 stimulation, as well as long-lasting, delayed, reductions in cocaine taking and cocaine seeking with combined M 1 /M 4 receptor stimulation or with M 1 stimulation alone. M 4 stimulation opposes dopaminergic signaling acutely, but direct dopamine receptor antagonists have proved unhelpful in managing cocaine use disorder because they lose efficacy with long-term administration. It is therefore critical to determine whether M 4 approaches themselves can remain effective with repeated or chronic dosing. We assessed the effects of repeated administration of the M 4 positive allosteric modulator (PAM) VU0152099 in rats trained to choose between intravenous cocaine and a liquid food reinforcer, to obtain quantitative measurement of whether M 4 stimulation could produce delayed and lasting reduction in cocaine taking. VU0152099 produced progressively augmenting suppression of cocaine choice and cocaine intake, but produced neither rebound nor lasting effects after treatment ended. To compare and contrast effects of M 1 vs. M 4 stimulation, we tested whether the M 4 PAM VU0152100 suppressed cocaine self-administration in mice lacking CalDAG-GEFI signaling factor, required for M 1 -mediated suppression of cocaine self-administration. CalDAG-GEFI ablation had no effect on M 4 -mediated suppression of cocaine self-administration. These findings support the potential usefulness of M 4 PAMs as pharmacotherapy to manage cocaine use disorder, alone or in combination with M 1 -selective ligands, and show that M 1 and M 4 stimulation modulate cocaine-taking behavior by distinct mechanisms.